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Vasileios Zochios1,2 and
Aristotle D Protopapas3
Cardiac failure is a major global killer.1
Orthotopic heart transplantation is the
resource-intensive surgical treatment of
choice for end-stage cardiac failure.2 Its
main and worsening limitation is paucity of
donors. This is a sobering reality that calls
for donor organ stewardship and ultimately
disruptive technological solutions in order to
reduce the worldwide waiting lists for ortho-
topic heart transplantation. We have noted
the increasing complexity of allocation and
managing of finite resources in procurement
(known as retrieval in the UK) of donor
hearts. The three donation factors impacting
on the outcomes of orthotopic heart trans-
plantation are, in no particular order, donor
age, donor cardiovascular history (especially
stroke as the cause of death) and cold ischae-
mia time.3 Most of the cadaveric donors
have suffered brain death (Donor Brain
Death [DBD]), whilst options on donors
from cardiac death (Donor Cardiac Death
[DCD]) have already been popularized in
the last decade.4
With the aforementioned predicament in
mind, we offer a viewpoint on an emerging
relevant technology known as organ care
systems (OCS). These have for some time
been used to optimise the donation of
abdominal organs, especially liver and
kidney.5 In liver procurement for example,
the OCS scavenges harmful particles.5
It follows that the OCS concept
could be applied to orthotopic heart trans-
plantation.6 At least two systems, one from
a New England manufacturer in the US
that is already in clinical use and another
Swedish system with reported porcine suc-
cess that is pending human application
(Personal Communication), are currently
being used in Europe.6 The primary adver-
tised advantage of an OCS is the almost
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complete removal of the aforementioned
cold ischaemia time; the latter measured
from application of the aortic cross clamp
(in donation after brainstem death) or asys-
tole (in donation after circulatory death)
until in situ reperfusion of the donated
heart. The input of pioneering cardiovascu-
lar perfusion practitioners has been pivotal
so far in developing and managing the pro-
totype apparatus.
The system from the New England man-
ufacturer, the only clinically available
system to date, enjoys investigatory device
status in the UK and the rest of Europe.6
There have been more than 200 runs from
six UK cardiac procurement (retrieval)
centres during the last two financial years,
a figure that will be intensified henceforth as
various funding avenues are being explored.
The obvious aim is to obtain approval from
The US Food & Drug Administration
on the strength of favourable outcomes in
the UK and Europe. The retail cost is con-
siderable; tens of thousands of pounds per
heart procured, exceeding roughly a tenth
of that of the entire care bundle of an
orthotopic heart transplant. The Swedish
system is in the early stages of recruitment
for a pilot study in humans and will not be
discussed further.
The prototype OCS we use currently in
the UK holds theoretical, scientific and clin-
ical interest for perioperative physicians
tasked with the care of the DBD donor
from transferral from the intensive care
unit until aortic cross clamping. We shall
not, however, belabour the surgical consid-
erations of the system from the New
England manufacturer in this editorial. In
brief, following cardiectomy, the donor
heart is inspected for defects, in particular
patent foramen ovale, and then directly
inserted under aseptic conditions and with-
out topical cooling into the specialized
chamber by means of aortic cannulation
and pulmonary artery venting. Electric car-
dioversion for asystolic hearts may be
required, especially in the DCD, and the
module incorporates various ingenious sol-
utions for monitoring vital signs, metabo-
lites and it can provide cardiac massage if
required (see supplemental video of the car-
diac OCS in operation).
Appropriate invasive haemodynamic
monitoring (invasive arterial systemic
blood pressure and pulmonary arterial pres-
sure monitoring), dynamic assessment of
volume status and responsiveness (combi-
nation of haemodynamic and echocardio-
graphic parameters), thermoregulation and
appropriate muscle relaxation are para-
mount in successful organ procurement.
Apart from the standard cardiopulmonary
and anaesthetic considerations during
organ donation surgery, nuances of OCS
management relevant to the anaesthetist
and intensivist involved in cardiac OCS
retrieval can be formalised into three
broad metabolomic aspects: (i) mainte-
nance of normoglycaemia (often requires
insulin infusion); (ii) tight electrolyte
(potassium and sodium in particular) con-
trol, and selection of the appropriate solu-
tion regimen; and (iii) permissive
gravitational (siphoning) exsanguination
of 1.0–1.5 l of donor blood through a
single-stage right atrial cannula. For obvi-
ous reasons, the latter happens immediately
before the cold ischaemia time, as loss of
such volume may destabilize the donor.
Implementation of the aforementioned
intraoperative strategies and a multidiscipli-
nary perioperative approach (operating
room and donor care practitioners, inten-
sivists, perioperative physicians, retrieval
surgeons) may have an effect on graft via-
bility and ultimately determine the outcome
of the organ recipient.
The New England manufacturers assert
that their OCS negates the cold ischaemia
time, in so much that the cold ischaemia
time stops for the heart once it has been
connected via the ascending aortic and pul-
monary cannulation to the OCS.
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There is a paucity of large-scale prospec-
tive studies examining the effect of cardiac
OCS on patient-relevant outcomes (Table 1),
and ultimately, donation stewardship.7–13
Unfortunately, the included studies were
either underpowered for their primary end-
point or had undefined outcomes.7–13
Summarising what a perioperative physi-
cian caring for a cardiac donor after brain
death using cardiac OCS in a district gener-
al hospital should henceforth bear in mind,
we note the importance of metabolomic
management and most crucially, the vigi-
lance around the exsanguination pre-
clamping, because a volume loss may
render the donor unstable.
It therefore remains unknown whether
cardiac OCS in its present or future guises
will confer a cost-effective benefit compared
with cold storage preservation. Little has so
far been asserted on the cost-effectiveness
of expensive cardiac OCS for procurement.
The assertion of minimising cold
ischaemia time remains to be tested. The
potential of cardiac OCS to expand
cardiac donations, especially with regard
to donations after cardiac death, would be
most welcome.
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